Sources
Investors
Series A$58M2026-10-069 investors
Angelini Ventures[ LEAD ]
BioGeneration Ventures[ LEAD ]
European Investment Bank (EIB)[ LEAD ]
Kurma Partners[ LEAD ]
- Epidarex Capital
- Kerna Ventures
A preclinical-stage biotechnology company developing potential first-in-class, disease-modifying therapies for rare vascular diseases
Rome, ItalyBiotech
3 sources · checked 1 time, last 33m ago
The headline calls EIB a co-lead, while the release body describes EIB as providing support via Angelini Ventures’ vehicle; EIB is retained as a lead because the source explicitly calls it co-lead.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series A | $58M | 2026-10-06 | Angelini Ventures, BioGeneration Ventures, European Investment Bank (EIB), Kurma Partners | 2 outlets. #67 in Trending |
3 sources · checked 1 time, last 33m ago [ VERIFIED · CORRECTED ] read against 2 of 3 sources
The headline calls EIB a co-lead, while the release body describes EIB as providing support via Angelini Ventures’ vehicle; EIB is retained as a lead because the source explicitly calls it co-lead. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]3 pages read: finance.yahoo.com, globenewswire.com, manilatimes.net·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 2 of 3 sources | ||||